諾普信(002215.SZ):產業基金擬增資公司三級子公司廣東諾禾
格隆匯5月14日丨諾普信(002215.SZ)公佈,廣東諾普信一創產業投資基金合夥企業(有限合夥)(以下簡稱“產業基金”)擬與公司及公司三級全資子公司廣東諾禾農業科技有限公司(以下簡稱“廣東諾
禾”或“標的公司”)等共同簽署《廣東諾普信一創產業投資基金合夥企業(有
限合夥)與深圳百盛農業科技服務有限公司及深圳諾普信農化股份有限公司關於
標的公司廣東諾禾農業科技有限公司之投資協議》。
產業基金擬出資8000萬元人民幣增資標的公司,其中4803.9216萬元人民
幣計入註冊資本,其餘3196.0784萬元人民幣作為廣東諾禾的資本公積金。公司
同意上述增資,並放棄對上述增資的優先認購權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.